Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quigley Corporation subsidiary Quigley Pharma has obtained positive results for its QR-443 compound for the treatment of cachexia, a debilitating and life-threatening muscle wasting condition, in an animal model.
Subscribe to our email newsletter
The results of the study indicated that 75% of tested mice injected with 5mg of QR-433 were protected from cachexia and did not exhibit any significant weight loss, compared to untreated control animals which exhibited a 15% to 25% weight loss at the end of the experiment.
QR-443 is an all natural broad spectrum anti-inflammatory compound that is being concurrently studied as a treatment for rheumatoid arthritis (under the designation QR-440) in humans and dogs. QR-443 has been shown in previous preclinical studies to inhibit the production of TNFa and IFN gamma, and reducing other inflammatory cytokines associated with cachexia.
“The significant findings of the study are sufficient to continue to the next stage of the drug development process. We plan to investigate the possibility of fast track status with the FDA,” stated Dr Richard Rosenbloom, COO of Quigley Pharma. “Alternatively, due to the importance of these findings, the company may consider launching this product as a neutraceutical.”